Groundbreaking Research from Abalos Therapeutics
-- Combination with bispecific T-cell engagers amplifies T-cell recruitment and cytotoxic activity against tumor cells --
Abalos Therapeutics is making headlines with the announcement of promising preclinical data regarding its lead drug candidate, ABX-001. This innovative treatment is demonstrating its potential to significantly enhance anti-tumor effects when combined with bispecific T-cell engagers.
At the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, Professor Karl S. Lang, a leading figure in immunology and the scientific founder of Abalos, will present these exciting findings. ABX-001 is designed to target cancer cells while minimizing impact on healthy tissues, setting the stage for a new frontier in cancer therapy.
ABX-001's Pioneering Mechanism of Action
The innovative formula of ABX-001 is centered on the strategic optimization of a non-lytic arenavirus strain. This approach harnesses advanced virus engineering to achieve both immunostimulatory and anti-tumoral properties that are crucial in treating advanced solid tumors. ABX-001 showcases robust anti-cancer activity across various tumor models, underscoring its potential relevance in the oncology field.
“We've harnessed the natural processes of mutation and selection combined with virus engineering to pioneer an immunotherapy that stands apart,” noted Jörg Vollmer, Chief Scientific Officer at Abalos. He emphasized that this newly revealed data indicates ABX-001 synergizes effectively with T-cell directed therapies, enhancing T-cell recruitment and resulting in strong anti-tumor responses. Such synergy could pave the way for more sustainable and effective treatments for patients battling solid tumors, an area where traditional immunotherapies often struggle.
Presentation Insights and Future Directions
Details surrounding the upcoming poster session include:
Abstract Title: Optimized arenavirus vectors with tumor-tropic mutations as new class of amplificators of anti-tumoral T-cell responses
Abstract Number: 828
Presentation Date: Saturday, November 8, 2025
Presenter: Prof. Karl S. Lang, PhD
The experiment's outcomes revealed that ABX-001 not only expands CD8+ T-cells—key players in the immune response—but also supports their transformation into potent effector cells targeting tumor cells. The safety profile of ABX-001 is notable, with studies indicating no severe adverse effects in various models, including immune-compromised mice and non-human primates. The combination of ABX-001 with bispecific T-cell engagers revealed significantly improved anti-tumor efficacy compared to usual monotherapy options.
About Abalos Therapeutics
Abalos Therapeutics stands at the forefront of a pioneering anti-cancer strategy that leverages the immune system's power to precisely target cancer cells. The company’s arenavirus-based drug candidates provoke robust adaptive and innate immune responses right within the tumor environment, launching an effective immune assault against both primary tumors and metastatic sites.
The organization's flagship product candidate, ABX-001, continues to display impressive efficacy and safety in preclinical research, and it currently is being evaluated in a Phase 1 trial for multiple advanced solid tumors. With a team composed of experienced biotech leaders and immunology experts, Abalos aims to redefine the landscape of immuno-oncology through innovative drug development.
For further inquiries, Abalos Therapeutics can be reached at their contact details:
Abalos Therapeutics GmbH
Phone: +49 211 540104-0
Email: info@abalos-tx.com
Frequently Asked Questions
What is ABX-001?
ABX-001 is an innovative anti-cancer drug candidate developed by Abalos Therapeutics, focusing on enhancing immune response against tumors.
What role do bispecific T-cell engagers play in the treatment?
Bispecific T-cell engagers amplify the immune response by triggering T-cells to attack tumor cells, potentially improving outcomes when combined with ABX-001.
When will the data from the SITC 2025 Annual Meeting be presented?
The presentation will occur on November 8, 2025, during the poster session at the conference.
How does Abalos Therapeutics ensure patient safety in their studies?
Abalos conducts comprehensive research to demonstrate a favorable safety profile for ABX-001, with clinical trials confirming minimal adverse effects in trial models.
Where can I find more information about Abalos Therapeutics?
Additional information is available on their website at www.abalos-tx.com.
